Literature DB >> 17220163

Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.

Jin Liu1, Hiroya Matsuo, Qin Xu, Wei Chen, Jiayin Wang, Takeshi Maruo.   

Abstract

BACKGROUND: This study was conducted to elucidate the effects of raloxifene on proliferation and apoptosis in cultured human uterine leiomyoma cells.
METHODS: The monolayer cultures were treated with graded concentrations (10(-9), 10(-8) and 10(-7) M) of raloxifene and 10(-7) M 17beta-estradiol (E(2)). Cell viability, percentage of proliferating cell nuclear antigen (PCNA)-positive cells, percentage of terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick-end labelling (TUNEL)-positive cells and the expression of PCNA and Bcl-2 proteins were assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxylphenyl)-2-(4-sulphophenyl)-2H-tetraz olium assay, immunocytochemistry, TUNEL assay and western blot analysis, respectively.
RESULTS: Compared with untreated cultures, the number of viable cultured cells, percentage of PCNA-positive cells and PCNA protein expression were significantly decreased by treatment with 10(-9) M raloxifene, but increased by treatment with either 10(-8) M or 10(-7) M raloxifene. In contrast, the percentage of TUNEL-positive cells was significantly increased and Bcl-2 protein expression was significantly decreased by treatment with 10(-9) M raloxifene, whereas they were not affected by treatment with either 10(-8) or 10(-7) M raloxifene.
CONCLUSIONS: In cultured leiomyoma cells, low concentration (10(-9) M) of raloxifene may inhibit the growth of leiomyoma cells, whereas high concentrations (10(-8) M, 10(-7) M) of raloxifene may promote their growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220163     DOI: 10.1093/humrep/del515

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

Review 1.  Macrophages and Immune Responses in Uterine Fibroids.

Authors:  Alessandro Zannotti; Stefania Greco; Pamela Pellegrino; Federica Giantomassi; Giovanni Delli Carpini; Gaia Goteri; Andrea Ciavattini; Pasquapina Ciarmela
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

2.  A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells.

Authors:  Xudong Di; Danica M K Andrews; Charles J Tucker; Linda Yu; Alicia B Moore; Xiaolin Zheng; Lysandra Castro; Tonia Hermon; Hang Xiao; Darlene Dixon
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

3.  Effects of tamoxifen on urinary incontinence: Case report and review of literature.

Authors:  Elshad Hasanov; Merve Hasanov; Issa M Kuria; Rovshan Hasanov; Reshad Rzazade; Eric Jonasch; Kadri Altundag
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Induction of mitochondrial apoptotic pathway by raloxifene and estrogen in human endometrial stromal ThESC cell line.

Authors:  Ivana Nikolic; Marija Andjelkovic; Milan Zaric; Ivanka Zelen; Petar Canovic; Zoran Milosavljevic; Marina Mitrovic
Journal:  Arch Med Sci       Date:  2016-05-12       Impact factor: 3.318

Review 5.  Current medical treatment of uterine fibroids.

Authors:  Geum Seon Sohn; SiHyun Cho; Yong Man Kim; Chi-Heum Cho; Mee-Ran Kim; Sa Ra Lee
Journal:  Obstet Gynecol Sci       Date:  2018-02-13

6.  Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.

Authors:  Youn-Jee Chung; Boah Chae; Se-Hyun Kwak; Jae-Yen Song; Ah-Won Lee; Hyun-Hee Jo; Young-Ok Lew; Jang-Heub Kim; Mee-Ran Kim
Journal:  Int J Med Sci       Date:  2014-01-28       Impact factor: 3.738

7.  Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells.

Authors:  Shu-Lan Lv; Rui Wang; Xue Xue; Lan-Bo Zhao; Xiao-Qian Tuo; Si-Jia Ma; Dong-Xin Liang; Yi-Ran Wang; Xue Feng; Qing Li; Qi Wang; Lu Han; Qi-Ling Li
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.